The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Majedie Investments Net Assets Fall As It Hikes Payout, Redeems Debt

Wed, 05th Dec 2018 11:56

LONDON (Alliance News) - Majedie Investments PLC on Wednesday reported a decrease in net asset value over its financial year due to making higher dividend payouts and redeeming debentures, as its biggest fund underperformed its benchmark.

At September 30, the investment trust's NAV per share with debt at par value was 334.3 pence, down 2.1.% compared to 341.6p last year. With debt at fair value, Majedie's NAV per share decreased slightly in the same period to 326.2p at September 30 from 327.8p the year before.

Majedie's NAV total return at par value was 0.9% and at fair value was 2.7%. The trust did, however, note the redemption of its 2020 9.5% debentures in December 2017, which diluted the NAV at par value by 1.6% and by 0.6% at fair value.

The trust said it redeemed the debenture in order to reduce its gearing "as markets were at all time highs". Majedie's gearing reduced to 10% at September 30 from 17% a year before.

A gearing ratio is a measure of financial leverage, meaning the degree to which a firm's operations are funded by equity capital versus creditor financing. A higher gearing ratio indicates a higher degree of leverage.

The trust's net assets decreased 2.1% to GBP178.6 million from GBP182.5 million last year.

Majedie's net assets were hurt by its increased dividend payout and by a premium paid on redeeming the 2020 debentures.

Majedie upped its total dividend payment for the year by 13% to 11.00 from the 9.75p last year.

The FTSE All Share Index rose by 5.9% in the period and the MSCI World Index gained 12.9%. Majedie has no overall benchmark; instead its funds have their own separate benchmarks.

The biggest contributors to the trust's net assets were funds run by its manager Majedie Asset Management. Majedie Investments holds a 17% stake in Majedie Asset Management.

Majedie Investments noted the Majedie Asset Management UK Equity Segregated portfolio, which represents 29% of Majedie Investments total assets, underperformed it benchmark.

The fund returned 3.0% net of fees to Majedie Investments, which is a 2.9% underperformance against its benchmark - the FTSE All Share Index. The biggest detractors from the fund were overweight positions in general retail, gold mining and fixed line telecoms. Specifically, overweight positions in Barrick Gold Corp and Saga PLC hurt the fund's performance, as was not holding AstraZeneca PLC, Majedie said.

Chief Executive Officer William Barlow said: "Against a background of rising political concerns notably Brexit in the UK, but also in the US and Europe and rising economic concerns as quantitative easing turns to quantitative tightening, interest rate rises due to inflationary concerns, early signs of leading economic indicators rolling over and the Chinese economy slowing; the company's positioning has been defensive throughout the year. In retrospect this was too early but the recent market turbulence suggests the defensive positioning will be more appropriate in the current year."

Shares in Majedie Investments were down 1.7% Wednesday at 264.50 pence each.

More News
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.